The German biotechnology company Biontech expects several vaccines from cancer based on mRNA within 5 years. About this General Director, Co-founder Biontech Ugur Shahin and Director for Medical Research by Ovela Tinchi, said in an interview with the La Repubblica newspaper, reports TASS.
According to the founders of the company, 15 anticancer vaccines undergo clinical trials, the most advanced phase is a vaccine against melanoma.
“We expect some of them in the next 5 years, as well as other new vaccines located in the phase of advanced clinical development,” they said.
One of the ways to combat cancer with vaccines based on matrix ribonucleic acid technology is to indicate scientists that they can “encourage the immune system to attack certain parts of cancer cells that are common to all one type tumors and which are not subject to mutations “thus cancer cells are recognized and destroyed.